BriaCell Therapeutics (TSE:BCT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BriaCell Therapeutics has announced promising results from their Phase 2 clinical trial, showcasing improved overall survival rates for metastatic breast cancer patients treated with their Bria-IMT™ combination therapy. The therapy demonstrated significant clinical benefits across various breast cancer subtypes, suggesting potential advancements in treatment options for this challenging condition.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
